Internal Medicine, Hematology & Oncology · Berkeley, CA
NPI
1104844174
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2001 Dwight Way
Berkeley, CA, 94704
Phone (510) 204-1591
Groups this clinician bills Medicare through
Medicare paid, 2024
$224K
3,020 services
Medicare patients, 2024
537
Average age 76
Drug cost, 2024
$9.3M
1,884 prescriptions
Company payments, 2025
$165K
From 52 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajesh Behl was code 99214 (office e&m - established), 1,167 times for 420 patients. In total Rajesh Behl billed 3,020 services in 23 codes, and Medicare paid $224K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,167 | 420 | $77.92 | $91K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 626 | 224 | $14.88 | $9,315 |
| 99233 Hospital E&M - Subsequent | Facility | 455 | 67 | $105.10 | $48K |
| 99215 Office E&M - Established | Office | 328 | 119 | $121.22 | $40K |
| 99213 Office E&M - Established | Office | 175 | 105 | $55.13 | $9,648 |
| 99223 Hospital E&M - Initial | Facility | 52 | 41 | $150.39 | $7,820 |
| 99232 Hospital E&M - Subsequent | Facility | 48 | 22 | $70.02 | $3,361 |
| 36512 Red Blood Cell Transfusion | Office | 42 | 11 | $88.74 | $3,727 |
| 38221 Other Organ Systems | Office | 41 | 35 | $63.61 | $2,608 |
| 99205 Office E&M - New | Office | 33 | 33 | $139.39 | $4,600 |
By year: 2022 $271K for 3,072 services; 2023 $271K for 2,969 services; 2024 $224K for 3,020 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajesh Behl prescribed most often to Medicare patients was Acyclovir, with 340 prescriptions and refills. In total Rajesh Behl wrote 1,884 Medicare prescriptions that cost $9.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 340 | 482 | 74 | $5,845 |
| Dexamethasone Generic | 114 | 138 | 32 | $2,379 |
| Hydroxyurea Generic | 102 | 230 | 25 | $2,251 |
| Xarelto Rivaroxaban | 79 | 164 | 19 | $90K |
| Jakafi Ruxolitinib Phosphate | 77 | 83 | Under 11 | $1.4M |
| Lenalidomide Generic | 76 | 76 | 14 | $1.2M |
| Revlimid Lenalidomide | 73 | 73 | 16 | $1.5M |
| Eliquis Apixaban | 70 | 93 | 15 | $53K |
| Venclexta Venetoclax | 58 | 61 | 11 | $411K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 55 | 61 | 15 | $211 |
| Prochlorperazine Maleate Generic | 53 | 53 | 42 | $693 |
| Imbruvica Ibrutinib | 47 | 47 | Under 11 | $724K |
| Xpovio Selinexor | 43 | 43 | Under 11 | $1.3M |
| Ondansetron Hcl Generic | 42 | 50 | 25 | $534 |
| Potassium Chloride Generic | 34 | 63 | 12 | $616 |
Brand drugs: 661 claims; generic drugs: 1,223 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajesh Behl $165K ($165K in general payments such as food, travel and fees) from 52 companies. The largest payer was Janssen Biotech, Inc. with $35K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 49 | $35K |
| Abbvie Inc. ABBV | 36 | $34K |
| Karyopharm Therapeutics Inc. KPTI | 19 | $27K |
| Genmab U.S., Inc. GMAB | 20 | $15K |
| Incyte Corporation INCY | 22 | $14K |
| Novartis Pharmaceuticals Corporation NVS | 11 | $13K |
| Kite Pharma, Inc. GILD | 18 | $11K |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $5,497 |
| Syndax Pharmaceuticals, Inc. SNDX | 6 | $4,387 |
| Invivyd Inc IVVD | 2 | $2,838 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.